A noticeable increase in cases of cardiovascular diseases worldwide is the factor majorly responsible for cardiac troponin market development.
Cardiac troponin is witnessing a sizable demand due to higher prevalence of acute coronary syndrome followed by rise in demand for point-of-care (POC) cardiac testing kits with higher specificity in detection of cardiac diseases in myocardial infarction.
The companies operating in cardiac troponin market are working toward low-noise fluorescent detection of the cardiac troponin I within human serum on the basis of surface acoustic wave (SAW) separation.
They are also exploring combination of glucose and high-sensitivity cardiac troponin in diagnosing acute myocardial infarction (AMI).
Cardiac troponin is a primary diagnostic biomarker meant to detect cardiac muscle injury. The timely and precise diagnosis from this biomarker plays a vital role in prevention of risks of heart attacks.
Tropinin I (cTnl) and troponin T (cTNT) are amongst the cardiac regulatory proteins involved in exercising control over calcium-mediated interaction between actin and myosin. As they are biomarkers for myocardial necrosis, the higher cardiac specificity renders them one of the preferred biomarkers to diagnose myocardial infarction.
As per the data published by the American Heart Association, Inc., a cohort study was conducted in January 2021 in order to evaluate effect of highly sensitive cardiac troponin T (hs-cTnT) amongst the U.S. population.
Study’s results have indicated that the ones symptomatic about Acute Coronary Syndrome (ACS) are treated by combining the hs-cTnT strategies with heart score and achieve passable performance regarding diagnosis of adverse cardiac events.
| Attribute | Detail |
|---|---|
| Market Drivers |
|
A troponin test performs the function of measuring levels of troponin T/troponin I proteins in blood. Such proteins are released when there is a severe damage caused to heart muscle, which indicates a heart attack. Damage to the heart is directly proportional to the quantity of troponin T and I in the blood.
As per the WHO, 38% of premature deaths worldwide are caused by cardiovascular diseases. It further states that early detection of cardiovascular diseases can prevent these deaths. Troponin tests can help in this detection.
In August 2022, the American College of Cardiology published the study stating that by the year 2060 the risk factor related to cardiovascular diseases will increase on an exponential count, thereby resulting in a marked rise in the number of patients for such diseases.
Rise in CVDs cases worldwide is thus accelerating the global cardiac troponin market.
The consumers are increasingly opting for troponin testing. Therefore, the key participants are emphasizing development of technologically advanced products in order to locate the untapped avenues. Such developments are likely to bolster the cardiac troponin industry.
In November 2022, the Department of Life Technologies of the University of Turku’s Biotechnology unit collaborated with the Heart Center of Turku University Hospital to develop a new-fangled cardiac troponin test that aimed to fast-track heart attack’s diagnosis.
In November 2022, OMRON Healthcare partnered with CardioSocial in order to develop early cardiovascular disease detection technologies to manage cardiac health. The partnership offers digital cardiac biomarkers.
In April 2021, Roche, using Elecsys technology (known for having NT-proBNP and sensitive cardiac troponin T), announced launching a series of five novel intended uses for two cTnT-hs. This improves risk diagnosis.
Continuous launching of new products is thus helping in maintaining higher vibration quotient for cardiac troponin market.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
As per the latest cardiac troponin market analysis, North America dominated the troponin assay industry in 2023 and the dominance is expected to continue during the forecast period. This is attributed to rise in prevalence of cardiovascular diseases all over the U.S. coupled with speedy approvals of new products by the regulatory authorities.
For instance, in December 2022, Quidel TriageTrue High-Sensitivity Troponin I (hsTnl) was approved by Health Canada for usage on Quidel Triage MeterPro platform. The test is reported to provide results in close to 20 minutes.
Europe’s significant cardiac troponin market share is due to approval of novel products with regulatory frameworks such as CE marks. Moreover, this region houses leading players such as Eurolyser Diagnostica GmbH and F. Hoffmann-La Roche Ltd.
As per the article published by the National Center for Biotechnology Information (NCBI), 60% of centers in Europe have adopted high-sensitivity assays for troponin testing.
Asia Pacific’s expansion of cardiac troponin market size is owing to growing awareness regarding the importance of cardiac troponin tests in countries such as India and China. As per news article published by the Times of India in April 2023, hospitals in India have witnessed a rise in these tests in the last few years.
It further mentions that Hiranandani Hospital, Mumbai alone witnessed a spike of 28.6% in the number of troponin tests in 2022 in comparison with 2021.
The cardiac troponin market manufacturers are engaged in launching new products to strengthen their position in the cardiac specific troponin landscape. For instance, in October 2022, HyTest Ltd introduced five novel antibodies specific for troponin C (cTnl).
These products are used for quantitative development of cTnl. In December 2020, DIALAB GmbH launched DIAQUICK Troponin T Cassette to expand their product offerings.
F. Hoffmann-La Roche Ltd., bioMérieux SA, Abbott Laboratories, Siemens Healthineers India, Eurolyser Diagnostica GmbH, QuidelOrtho Corporation, Beckman Coulter, Inc., Response Biomedical Corporation, and LifeSign LLC are some of the key players spanning the cardiac troponin market report scope.
These companies have been profiled based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.
| Attribute | Detail |
|---|---|
| Market Size in 2023 | US$ 4.5 Bn |
| Market Forecast (Value) in 2034 | US$ 11.5 Bn |
| Growth Rate (CAGR) | 8.9% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available Upon Request |
| Pricing | Available Upon Request |
It was valued at US$ 4.5 Bn in 2023
It is projected to advance at a CAGR of 8.9% from 2024 to 2034
Growing prevalence of cardiovascular diseases and increase in frequency of product launches by key players
Diagnostic laboratories accounted for the largest share in 2023
North America was the dominant region in 2023
F. Hoffmann-La Roche Ltd., bioMérieux SA, Abbott Laboratories, Siemens Healthineers India, Eurolyser Diagnostica GmbH, QuidelOrtho Corporation, Beckman Coulter, Inc., Response Biomedical Corporation, and LifeSign LLC
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cardiac Troponin Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Cardiac Troponin Market Analysis and Forecast, 2020-2034
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Cardiac Troponin Market Analysis and Forecast, by Troponin Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Troponin Type, 2020-2034
6.3.1. Troponin I
6.3.2. Troponin T
6.3.3. Troponin C
6.4. Market Attractiveness, by Troponin Type
7. Global Cardiac Troponin Market Analysis and Forecast, by Setting
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Setting, 2020-2034
7.3.1. Laboratory Setting
7.3.2. Point-of-Care (POC) Testing
7.4. Market Attractiveness, by Setting
8. Global Cardiac Troponin Market Analysis and Forecast, by Indication
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Indication, 2020-2034
8.3.1. Myocardial Infarction
8.3.2. Congestive Heart Failure
8.3.3. Acute Coronary Syndrome
8.3.4. Others (cardiomyopathy, etc.)
8.4. Market Attractiveness, by Indication
9. Global Cardiac Troponin Market Analysis and Forecast, by End-user
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2020-2034
9.3.1. Hospitals & Clinics
9.3.2. Diagnostic Laboratories
9.3.3. Homecare Settings
9.3.4. Others (Research Institutes, etc.)
9.4. Market Attractiveness, by End-user
10. Global Cardiac Troponin Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2020-2034
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region
11. North America Cardiac Troponin Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Troponin Type, 2020-2034
11.2.1. Troponin I
11.2.2. Troponin T
11.2.3. Troponin C
11.3. Market Attractiveness, by Troponin Type
11.4. Market Value Forecast, by Setting, 2020-2034
11.4.1. Laboratory Setting
11.4.2. Point-of-Care (POC) Testing
11.5. Market Attractiveness, by Setting
11.6. Market Value Forecast, by Indication, 2020-2034
11.6.1. Myocardial Infarction
11.6.2. Congestive Heart Failure
11.6.3. Acute Coronary Syndrome
11.6.4. Others (cardiomyopathy, etc.)
11.7. Market Attractiveness, by Indication
11.8. Market Value Forecast, by End-user, 2020-2034
11.8.1. Hospitals & Clinics
11.8.2. Diagnostic Laboratories
11.8.3. Homecare Settings
11.8.4. Others (Research Institutes, etc.)
11.9. Market Attractiveness, by End-user
11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By Troponin Type
11.11.2. By Setting
11.11.3. By Indication
11.11.4. By End-user
11.11.5. By Country
12. Europe Cardiac Troponin Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Troponin Type, 2020-2034
12.2.1. Troponin I
12.2.2. Troponin T
12.2.3. Troponin C
12.3. Market Attractiveness, by Troponin Type
12.4. Market Value Forecast, by Setting, 2020-2034
12.4.1. Laboratory Setting
12.4.2. Point-of-Care (POC) Testing
12.5. Market Attractiveness, by Setting
12.6. Market Value Forecast, by Indication, 2020-2034
12.6.1. Myocardial Infarction
12.6.2. Congestive Heart Failure
12.6.3. Acute Coronary Syndrome
12.6.4. Others (cardiomyopathy, etc.)
12.7. Market Attractiveness, by Indication
12.8. Market Value Forecast, by End-user, 2020-2034
12.8.1. Hospitals & Clinics
12.8.2. Diagnostic Laboratories
12.8.3. Homecare Settings
12.8.4. Others (Research Institutes, etc.)
12.9. Market Attractiveness, by End-user
12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By Troponin Type
12.11.2. By Setting
12.11.3. By Indication
12.11.4. By End-user
12.11.5. By Country/Sub-region
13. Asia Pacific Cardiac Troponin Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Troponin Type, 2020-2034
13.2.1. Troponin I
13.2.2. Troponin T
13.2.3. Troponin C
13.3. Market Attractiveness, by Troponin Type
13.4. Market Value Forecast, by Setting, 2020-2034
13.4.1. Laboratory Setting
13.4.2. Point-of-Care (POC) Testing
13.5. Market Attractiveness, by Setting
13.6. Market Value Forecast, by Indication, 2020-2034
13.6.1. Myocardial Infarction
13.6.2. Congestive Heart Failure
13.6.3. Acute Coronary Syndrome
13.6.4. Others (cardiomyopathy, etc.)
13.7. Market Attractiveness, by Indication
13.8. Market Value Forecast, by End-user, 2020-2034
13.8.1. Hospitals & Clinics
13.8.2. Diagnostic Laboratories
13.8.3. Homecare Settings
13.8.4. Others (Research Institutes, etc.)
13.9. Market Attractiveness, by End-user
13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By Troponin Type
13.11.2. By Setting
13.11.3. By Indication
13.11.4. By End-user
13.11.5. By Country/Sub-region
14. Latin America Cardiac Troponin Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Troponin Type, 2020-2034
14.2.1. Troponin I
14.2.2. Troponin T
14.2.3. Troponin C
14.3. Market Attractiveness, by Troponin Type
14.4. Market Value Forecast, by Setting, 2020-2034
14.4.1. Laboratory Setting
14.4.2. Point-of-Care (POC) Testing
14.5. Market Attractiveness, by Setting
14.6. Market Value Forecast, by Indication, 2020-2034
14.6.1. Myocardial Infarction
14.6.2. Congestive Heart Failure
14.6.3. Acute Coronary Syndrome
14.6.4. Others (cardiomyopathy, etc.)
14.7. Market Attractiveness, by Indication
14.8. Market Value Forecast, by End-user, 2020-2034
14.8.1. Hospitals & Clinics
14.8.2. Diagnostic Laboratories
14.8.3. Homecare Settings
14.8.4. Others (Research Institutes, etc.)
14.9. Market Attractiveness, by End-user
14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By Troponin Type
14.11.2. By Setting
14.11.3. By Indication
14.11.4. By End-user
14.11.5. By Country/Sub-region
15. Middle East & Africa Cardiac Troponin Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Troponin Type, 2020-2034
15.2.1. Troponin I
15.2.2. Troponin T
15.2.3. Troponin C
15.3. Market Attractiveness, by Troponin Type
15.4. Market Value Forecast, by Setting, 2020-2034
15.4.1. Laboratory Setting
15.4.2. Point-of-Care (POC) Testing
15.5. Market Attractiveness, by Setting
15.6. Market Value Forecast, by Indication, 2020-2034
15.6.1. Myocardial Infarction
15.6.2. Congestive Heart Failure
15.6.3. Acute Coronary Syndrome
15.6.4. Others (cardiomyopathy, etc.)
15.7. Market Attractiveness, by Indication
15.8. Market Value Forecast, by End-user, 2020-2034
15.8.1. Hospitals & Clinics
15.8.2. Diagnostic Laboratories
15.8.3. Homecare Settings
15.8.4. Others (Research Institutes, etc.)
15.9. Market Attractiveness, by End-user
15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
15.10.1. GCC Countries
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By Troponin Type
15.11.2. By Setting
15.11.3. By Indication
15.11.4. By End-user
15.11.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2023)
16.3. Company Profiles
16.3.1. F. Hoffmann-La Roche Ltd.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. bioMérieux SA
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Abbott Laboratories
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Siemens Healthineers India
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Eurolyser Diagnostica GmbH
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. QuidelOrtho Corporation
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Beckman Coulter, Inc.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Response Biomedical Corporation
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. LifeSign LLC
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
List of Tables
Table 01: Global Cardiac Troponin Market Size (US$ Bn) Forecast, by Troponin Type, 2020-2034
Table 02: Global Cardiac Troponin Market Size (US$ Bn) Forecast, by Setting, 2020-2034
Table 03: Global Cardiac Troponin Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 04: Global Cardiac Troponin Market Size (US$ Bn) Forecast, by Indication, 2020-2034
Table 05: Global Cardiac Troponin Market Size (US$ Bn) Forecast, by Region, 2020-2034
Table 06: North America Cardiac Troponin Market Size (US$ Bn) Forecast, by Country, 2020-2034
Table 07: North America Cardiac Troponin Market Size (US$ Bn) Forecast, by Troponin Type, 2020-2034
Table 08: North America Cardiac Troponin Market Size (US$ Bn) Forecast, by Setting, 2020-2034
Table 09: North America Cardiac Troponin Market Size (US$ Bn) Forecast, by Indication, 2020-2034
Table 10: North America Cardiac Troponin Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 11: Europe Cardiac Troponin Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 12: Europe Cardiac Troponin Market Size (US$ Bn) Forecast, by Troponin Type, 2020-2034
Table 13: Europe Cardiac Troponin Market Size (US$ Bn) Forecast, by Setting, 2020-2034
Table 14: Europe Cardiac Troponin Market Size (US$ Bn) Forecast, by Indication, 2020-2034
Table 15: Europe Cardiac Troponin Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 16: Asia Pacific Cardiac Troponin Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 17: Asia Pacific Cardiac Troponin Market Size (US$ Bn) Forecast, by Troponin Type, 2020-2034
Table 18: Asia Pacific Cardiac Troponin Market Size (US$ Bn) Forecast, by Setting, 2020-2034
Table 19: Asia Pacific Cardiac Troponin Market Size (US$ Bn) Forecast, by Indication, 2020-2034
Table 20: Asia Pacific Cardiac Troponin Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 21: Latin America Cardiac Troponin Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 22: Latin America Cardiac Troponin Market Size (US$ Bn) Forecast, by Troponin Type, 2020-2034
Table 23: Latin America Cardiac Troponin Market Size (US$ Bn) Forecast, by Setting, 2020-2034
Table 24: Latin America Cardiac Troponin Market Size (US$ Bn) Forecast, by Indication, 2020-2034
Table 25: Latin America Cardiac Troponin Market Size (US$ Bn) Forecast, by End-user, 2020-2034
Table 26: Middle East & Africa Cardiac Troponin Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034
Table 27: Middle East & Africa Cardiac Troponin Market Size (US$ Bn) Forecast, by Troponin Type, 2020-2034
Table 28: Middle East & Africa Cardiac Troponin Market Size (US$ Bn) Forecast, by Setting, 2020-2034
Table 29: Middle East & Africa Cardiac Troponin Market Size (US$ Bn) Forecast, by Indication, 2020-2034
Table 30: Middle East & Africa Cardiac Troponin Market Size (US$ Bn) Forecast, by End-user, 2020-2034
List of Figures
Figure 01: Global Cardiac Troponin Market Size (US$ Bn), by Region, 2023 and 2034
Figure 02: Global Cardiac Troponin Market Revenue (US$ Bn), by Troponin Type, 2023
Figure 03: Global Cardiac Troponin Market Value Share, by Troponin Type, 2023
Figure 04: Global Cardiac Troponin Market Revenue (US$ Bn), by Setting, 2023
Figure 05: Global Cardiac Troponin Market Value Share, by Setting, 2023
Figure 06: Global Cardiac Troponin Market Revenue (US$ Bn), by Indication, 2023
Figure 07: Global Cardiac Troponin Market Value Share, by Indication, 2023
Figure 08: Global Cardiac Troponin Market Revenue (US$ Bn), by End-user, 2023
Figure 09: Global Cardiac Troponin Market Value Share, by End-user, 2023
Figure 10: Global Cardiac Troponin Market Value Share, by Region, 2023
Figure 11: Global Cardiac Troponin Market Value (US$ Bn) Forecast, 2020-2034
Figure 12: Global Cardiac Troponin Market Value Share Analysis, by Troponin Type, 2023 and 2034
Figure 13: Global Cardiac Troponin Market Attractiveness Analysis, by Troponin Type, 2024-2034
Figure 14: Global Cardiac Troponin Market Value Share Analysis, by Setting, 2023 and 2034
Figure 15: Global Cardiac Troponin Market Attractiveness Analysis, by Setting, 2024-2034
Figure 16: Global Cardiac Troponin Market Value Share Analysis, by Indication, 2023 and 2034
Figure 17: Global Cardiac Troponin Market Attractiveness Analysis, by Indication, 2024-2034
Figure 18: Global Cardiac Troponin Market Revenue (US$ Bn), by End-user, 2023
Figure 19: Global Cardiac Troponin Market Value Share, by End-user, 2023
Figure 20: Global Cardiac Troponin Market Value Share Analysis, by Region, 2023 and 2034
Figure 21: Global Cardiac Troponin Market Attractiveness Analysis, by Region, 2024-2034
Figure 22: North America Cardiac Troponin Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 23: North America Cardiac Troponin Market Attractiveness Analysis, by Country, 2024-2034
Figure 24: North America Cardiac Troponin Market Value Share Analysis, by Country, 2023 and 2034
Figure 25: North America Cardiac Troponin Market Value Share Analysis, by Troponin Type, 2023 and 2034
Figure 26: North America Cardiac Troponin Market Value Share Analysis, by Setting, 2023 and 2034
Figure 27: North America Cardiac Troponin Market Value Share Analysis, by Indication, 2023 and 2034
Figure 28: North America Cardiac Troponin Market Value Share Analysis, by End-user, 2023 and 2034
Figure 29: North America Cardiac Troponin Market Attractiveness Analysis, by Troponin Type, 2024-2034
Figure 30: North America Cardiac Troponin Market Attractiveness Analysis, by Setting, 2024-2034
Figure 31: North America Cardiac Troponin Market Attractiveness Analysis, by Indication, 2024-2034
Figure 32: North America Cardiac Troponin Market Attractiveness Analysis, by End-user, 2024-2034
Figure 33: Europe Cardiac Troponin Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 34: Europe Cardiac Troponin Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 35: Europe Cardiac Troponin Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 36: Europe Cardiac Troponin Market Value Share Analysis, by Troponin Type, 2023 and 2034
Figure 37: Europe Cardiac Troponin Market Value Share Analysis, by Setting, 2023 and 2034
Figure 38: Europe Cardiac Troponin Market Value Share Analysis, by Indication, 2023 and 2034
Figure 39: Europe Cardiac Troponin Market Value Share Analysis, by End-user, 2023 and 2034
Figure 40: Europe Cardiac Troponin Market Attractiveness Analysis, by Troponin Type, 2024-2034
Figure 41: Europe Cardiac Troponin Market Attractiveness Analysis, by Setting, 2024-2034
Figure 42: Europe Cardiac Troponin Market Attractiveness Analysis, by Indication, 2024-2034
Figure 43: Europe Cardiac Troponin Market Attractiveness Analysis, by End-user, 2024-2034
Figure 44: Asia Pacific Cardiac Troponin Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 45: Asia Pacific Cardiac Troponin Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 46: Asia Pacific Cardiac Troponin Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 47: Asia Pacific Cardiac Troponin Market Value Share Analysis, by Troponin Type, 2023 and 2034
Figure 48: Asia Pacific Cardiac Troponin Market Value Share Analysis, by Setting, 2023 and 2034
Figure 49: Asia Pacific Cardiac Troponin Market Value Share Analysis, by Indication, 2023 and 2034
Figure 50: Asia Pacific Cardiac Troponin Market Value Share Analysis, by End-user, 2023 and 2034
Figure 51: Asia Pacific Cardiac Troponin Market Attractiveness Analysis, by Troponin Type, 2024-2034
Figure 52: Asia Pacific Cardiac Troponin Market Attractiveness Analysis, by Setting, 2024-2034
Figure 53: Asia Pacific Cardiac Troponin Market Attractiveness Analysis, by Indication, 2024-2034
Figure 54: Asia Pacific Cardiac Troponin Market Attractiveness Analysis, by End-user, 2023-2034
Figure 55: Latin America Cardiac Troponin Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 56: Latin America Cardiac Troponin Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 57: Latin America Cardiac Troponin Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 58: Latin America Cardiac Troponin Market Value Share Analysis, by Troponin Type, 2023 and 2034
Figure 59: Latin America Cardiac Troponin Market Value Share Analysis, by Setting, 2023 and 2034
Figure 60: Latin America Cardiac Troponin Market Value Share Analysis, by Indication, 2023 and 2034
Figure 61: Latin America Cardiac Troponin Market Value Share Analysis, by End-user, 2023 and 2034
Figure 62: Latin America Cardiac Troponin Market Attractiveness Analysis, by Troponin Type, 2024-2034
Figure 63: Latin America Cardiac Troponin Market Attractiveness Analysis, by Setting, 2024-2034
Figure 64: Latin America Cardiac Troponin Market Attractiveness Analysis, by Indication, 2024-2034
Figure 65: Latin America Cardiac Troponin Market Attractiveness Analysis, by End-user, 2024-2034
Figure 66: Middle East & Africa Cardiac Troponin Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034
Figure 67: Middle East & Africa Cardiac Troponin Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 68: Middle East & Africa Cardiac Troponin Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 69: Middle East & Africa Cardiac Troponin Market Value Share Analysis, by Troponin Type, 2023 and 2034
Figure 70: Middle East & Africa Cardiac Troponin Market Value Share Analysis, by Setting, 2023 and 2034
Figure 71: Middle East & Africa Cardiac Troponin Market Value Share Analysis, by Indication, 2023 and 2034
Figure 72: Middle East & Africa Cardiac Troponin Market Value Share Analysis, by End-user, 2023 and 2034
Figure 73: Middle East & Africa Cardiac Troponin Market Attractiveness Analysis, by Troponin Type, 2024-2034
Figure 74: Middle East & Africa Cardiac Troponin Market Attractiveness Analysis, by Setting, 2024-2034
Figure 75: Middle East & Africa Cardiac Troponin Market Attractiveness Analysis, by Indication, 2024-2034
Figure 76: Middle East & Africa Cardiac Troponin Market Attractiveness Analysis, by End-user, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Cardiac Troponin Market
